ArticleFrontiers in neuroscience2026
Syncope in AQP4-IgG-positive neuromyelitis optica spectrum disorder: a case series and literature review.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To report two cases of aquaporin-4 immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica spectrum disorder (NMOSD) with syncope and to review previously documented cases, aiming to enhance recognition of this neurological manifestation and guide timely intervention. Methods: We reported two NMOSD cases presenting with syncope. A literature search was conducted in PubMed using Medical Subject Headings (MeSH) and relevant keywords related to NMOSD, area postrema syndrome, and syncope. Results: The two patients, a 40-year-old man and a 41-year-old woman, presented with area postrema syndrome (APS) and recurrent syncope. The syncope attacks were transient, characterized by sudden loss of consciousness and spontaneous recovery. Electrocardiograms on admission were unremarkable in both cases. MRI showed dorsal medullary oblongata lesions. Both were treated with high-dose intravenous methylprednisolone followed by maintenance inebilizumab, leading to complete clinical remission, seroconversion to AQP4-IgG negativity, and an Expanded Disability Status Scale (EDSS) score of 0 at last follow-up. Besides, a total of 16 cases were identified and reviewed in this study, including our cases. The cohort showed equal sex distribution (male-to-female ratio 1:1) and a mean age of 53.94 years. All patients presented with APS preceding syncope, and neuroimaging revealed medulla oblongata lesions. Electrocardiographic abnormalities were documented in eight patients, all presenting with sinus arrest. Considering the possible mechanisms of syncope in these patients, eight patients had sinus arrest, two had orthostatic hypotension, and two experienced cardiorespiratory arrest. Among the eight patients with sinus arrest, six underwent cardiac interventions (75%): TPM implantation in four (one also undergoing cardioneuroablation) and PPM implantation in two. Two patients (25%) achieved remission with IVMP alone without cardiac intervention. All 16 patients remained free of syncope during follow-up. Conclusion: Syncope may be an underrecognized manifestation of AQP4-IgG-positive NMOSD. Patients presenting with APS should be screened for syncope attacks, which may require emergency pacemaker implantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.